camrelizumab + famitinib

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced NSCLCNon-small Cell Lung Cancer

Phase 3

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.Non-small Cell Lung Cancer

Start: 2022-09-08End: 2025-12-31Target: 450Updated: 2022-11-17

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

TerminatedNCT05106335

Jiangsu HengRui Medicine Co., Ltd.Advanced NSCLC

Start: 2022-01-06End: 2022-05-11Updated: 2023-08-16

Related Papers

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Journal for ImmunoTherapy of Cancer2024-02-0110 citations

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Journal for ImmunoTherapy of Cancer2023-02-0118 citations